IP Library › Granted Patent US 10,543,277
Granted Patent B2
US 10,543,277 · App. 14/698,944 · Granted Jan 28, 2020

Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof

Inventors: Benny Antony (Ankamaly, IN); Moni Abraham Kuriakose (Ernakulam, IN)
Assignee: ARJUNA NATURAL PRIVATE LIMITED
A61K47/46A61K9/0053A61K31/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,543,277
App. No.
14/698,944
Granted
Jan 28, 2020
Kind
B2
Abstract

A medicinal composition useful for the treatment of head and neck cancer premalignant lesions. The composition includes a curcuminoid mixture and an essential oil of turmeric. The curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin. The essential oil of turmeric includes about 45% ar-turmerone. The weight ratio of curcuminoid mixture to essential oil of turmeric ranges from about 1:3 to about 99:1. Methods of preparation of the composition is provide. Methods of treatment of head and neck cancer premalignant lesions by oral administration is provided.

Claims (8)

1. A method of treating premalignant lesions of the head and neck in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition that enhances bioavailability of curcumin, the composition comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and the essential oil of turmeric comprises about 45% ar-turmerone, wherein the weight ratio of the curcuminoid mixture to the essential oil of turmeric ranges from about 1:3 to about 99:1, and wherein the enhanced bioavailability of curcumin in the subject ranges from more than 2 fold to about 16 fold.

2. A method of decreasing the size of premalignant lesions of the head and neck in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition that enhances bioavailability of curcumin, the composition comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and the essential oil of turmeric comprises about 45% ar-turmerone, wherein the weight ratio of the curcuminoid mixture to the essential oil of turmeric ranges from about 1:3 to about 99:1, and wherein the enhanced bioavailability of curcumin in the subject ranges from more than 2 fold to about 16 fold.

3. A method of inhibiting malignant transformation of premalignant lesions of the head and neck in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition that enhances bioavailability of curcumin, the composition comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and the essential oil of turmeric comprises about 45% ar-turmerone, wherein the weight ratio of the curcuminoid mixture to the essential oil of turmeric ranges from about 1:3 to about 99:1, and wherein the enhanced bioavailability of curcumin in the subject ranges from more than 2 fold to about 16 fold.

4. A method of inhibiting the occurrence of premalignant lesions in the head and neck in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition that enhances bioavailability of curcumin, the composition comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and the essential oil of turmeric comprises about 45% ar-turmerone, wherein the weight ratio of the curcuminoid mixture to the essential oil of turmeric ranges from about 1:3 to about 99:1, and wherein the enhanced bioavailability of curcumin in the subject ranges from more than 2 fold to about 16 fold.

5. A method of improving quality of life in a patient with head and neck premalignant lesions, the method comprising administering to the patient an effective amount of a composition that enhances bioavailability of curcumin, the composition comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and the essential oil of turmeric comprises about 45% ar-turmerone, wherein the weight ratio of the curcuminoid mixture to the essential oil of turmeric ranges from about 1:3 to about 99:1, and wherein the enhanced bioavailability of curcumin in the patient ranges from more than 2 fold to about 16 fold.

6. A method of decreasing symptoms associated with head and neck oral premalignant lesions in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition that enhances bioavailability of curcumin, the composition comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and the essential oil of turmeric comprises about 45% ar-turmerone, wherein the weight ratio of the curcuminoid mixture to the essential oil of turmeric ranges from about 1:3 to about 99:1, and wherein the enhanced bioavailability of curcumin in the subject ranges from more than 2 fold to about 16 fold.

7. A method of treating oral premalignant lesions in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition that enhances bioavailability of curcumin, the composition comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and the essential oil of turmeric comprises about 45% ar-turmerone, wherein the weight ratio of the curcuminoid mixture to the essential oil of turmeric ranges from about 1:3 to about 99:1, wherein the composition is orally administered in a dosage of about 500 mg/dose three times daily, and wherein the enhanced bioavailability of curcumin in the subject ranges from more than 2 fold to about 16 fold.

8. The method of treating premalignant lesions of claim 1 , wherein the composition is orally administered at a dosage of about 500 mg/dose three times daily for six months.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2016
From: ANTONY, BENNY; KURIAKOSE, MONI ABRAHAM
To: ARJUNA NATURAL EXTRACTS, LTD.
Reel/Frame 040202/0645 →
Priority Claims (2)
IN 950CHE2010 · Apr 5, 2010 · national
IN 4128CHE2012 · Nov 3, 2012 · national
Continuity (23)
Continuation PCTIN2013000673 · Oct 31, 2013
Continuation In Part 14476555 · Sep 3, 2014
Division 13645031 · Oct 4, 2012
Division 14698944
Continuation In Part 14623608 · Feb 17, 2015
Continuation In Part 14520292 · Oct 21, 2014
Continuation In Part 14206044 · Mar 12, 2014
Continuation In Part PCTIN2011000232 · Apr 4, 2011
Division 13674249 · Nov 12, 2012
Division 13506572 · Apr 30, 2012
Division 12926980 · Dec 21, 2010
Division 12073864 · Mar 11, 2008
Continuation In Part 11635599 · Dec 8, 2006
Division 13385717 · Mar 5, 2012
Division 12926985 · Dec 21, 2010
Division 12662740 · Apr 30, 2010
Division 11635599 · Dec 8, 2006
Continuation PCTIN2005000176 · May 30, 2005
Continuation In Part 13645031
Continuation In Part 13674249
Continuation In Part 14094725 · Dec 2, 2013
Provisional Application 61794175 · Mar 15, 2013
Related Publication 20160008479A1 · Jan 14, 2016
Cited By (1)
US 12,251,415